

CLINICAL REVIEW

Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes

*Thys van der Molen^a, Mario Cazzola^b^a Department of General Practice, University Medical Center Groningen, Groningen, The Netherlands^b Medicina Interna, Università di Roma Tor Vergata, Rome, Italy

Received 15th June 2011; revised 26th August 2011; accepted 9th September 2011; online 5th January 2012

Abstract

Bronchodilators are central to the management of chronic obstructive pulmonary disease (COPD). Clinical studies combining different classes of bronchodilators, in particular a long-acting muscarinic antagonist (LAMA) and a long-acting β_2 -agonist (LABA), have demonstrated greater improvements in lung function (forced expiratory volume in 1 second, FEV₁) in patients with COPD than monotherapy. FEV₁ has served as an important diagnostic measurement of COPD, and the majority of clinical studies of currently available pharmacotherapies grade effectiveness of treatment regimens based on improvements in FEV₁. However, FEV₁ alone may not adequately reflect the overall health status of the patient. Published evidence suggests that LABA/LAMA combination therapies demonstrate greater improvements in patient-centred outcomes such as dyspnoea, symptoms, rescue medication use, and quality of life than individual drugs used alone. Evaluating patient-centred outcomes associated with COPD is likely to play an important role in future research as a measure of overall treatment effectiveness. Raising awareness of the importance of outcomes beyond lung function alone, particularly in primary care where most patients initially present themselves for medical evaluation, should form a fundamental part of a more holistic approach to COPD management.

© 2012 Primary Care Respiratory Society UK. All rights reserved.

T van der Molen and M Cazzola. *Prim Care Respir J* 2012; 21(1): 101-108<http://dx.doi.org/10.4104/pcrj.2011.00102>**Keywords** COPD, bronchodilators, combination therapy, long-acting muscarinic antagonists, long-acting β_2 -agonists, patient-centred outcomes**Introduction**

Bronchodilators are the cornerstone of pharmacological management of chronic obstructive pulmonary disease (COPD), and current guidelines recommend their use as first-line therapy in symptomatic patients with airflow limitation.^{1,2}

Short-acting bronchodilators are typically used for immediate relief of symptoms, with long-acting agents being preferred as maintenance therapy to prevent or reduce symptoms.^{3,4}

For patients whose symptoms are not sufficiently controlled by maintenance monotherapy, the combined use of bronchodilators of different classes – in particular an inhaled muscarinic antagonist and a β_2 -agonist – is a favoured strategy for maximising bronchodilation in COPD.¹ Using this combined approach, bronchodilation is obtained both directly, through stimulation of β_2 -adrenergic receptors using β_2 -agonists, and indirectly, by inhibiting the action of acetylcholine at muscarinic

receptors using muscarinic antagonists. This proposed pharmacological interaction is supported by clinical evidence which suggests that combinations of long-acting β_2 -agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) result in significantly greater improvements in lung function (forced expiratory volume in 1 second, FEV₁) than with individual components,^{5,6} and that such improvements are maintained in the long term.^{7,8}

Although improving lung function is a key goal of COPD pharmacotherapy, FEV₁ measurements alone may not adequately reflect the impact of a treatment on a patient, and improvements in patient-centred outcomes such as symptoms, dyspnoea, and health status may better reflect the effectiveness of a particular pharmacotherapy.^{9,10} Furthermore, alternative outcome measures may better reflect the overall clinical status of the patient, and may be more significant to patients day-to-day.¹¹

* **Corresponding author:** Professor Thys van der Molen, Department of General Practice, University Medical Center Groningen, PO Box 196, Groningen 9700AD, The Netherlands. Tel: +31 503 637 478 E-mail: t.van.der.molen@med.umcg.nl

Clinical investigations of LABA/LAMA combinations have included patient-centred outcomes as study endpoints; however, available study data have not been systematically evaluated by outcome. This review examines the clinical evidence published to date for the use of LABA/LAMA

combinations in COPD, with a focus on outcomes beyond FEV₁ alone (see trial overview in Table 1). All trials administered tiotropium and indacaterol once daily and formoterol, arformoterol and salmeterol twice daily, unless otherwise stated.

Table 1. Clinical trial characteristics: randomised studies of long-acting β_2 -agonists combined with long-acting muscarinic antagonists

Authors	Design/duration	Patient characteristics (FEV ₁ % predicted*) mean FEV ₁ # GOLD stage II† patient number	Treatment groups	Outcomes measured
Formoterol plus tiotropium				
van Noord <i>et al.</i> 2006 ²	Randomised, open-label, crossover/2-week treatment periods	COPD (≤ 60) mean FEV ₁ : 38 GOLD stage II: 41 n=95	1. Tiotropium 18 μ g qd 2. Tiotropium 18 μ g qd + formoterol 12 μ g qd 3. Tiotropium 18 μ g qd + formoterol 12 μ g bid	Serial 24-hr spirometry (FEV ₁ , FVC) and resting IC on day 1 and at 2 weeks; diary card PEF; use of salbutamol as rescue; safety
Berton <i>et al.</i> 2010 ¹⁶	Randomised, double-blind, crossover/2-week treatment periods	COPD (< 70) mean FEV ₁ : 47.4 GOLD stage II: NS n=33	1. Formoterol 12 μ g bid 2. Tiotropium 18 μ g qd + formoterol 12 μ g bid	Spirometry (FEV ₁ , FVC, IC, residual volume, TLC); dyspnoea (TDI); cardiopulmonary exercise tests (CPX)
van Noord <i>et al.</i> 2005 ²³	Randomised, double-blind, crossover/6-week treatment periods	COPD (≤ 60) mean FEV ₁ : 37.2 GOLD stage II: 28 n=71	1. Tiotropium 18 μ g qd 2. Formoterol 12 μ g bid 3. Tiotropium 18 μ g qd + formoterol 12 μ g bid	Spirometry (FEV ₁ , FVC), use of salbutamol as rescue
Tashkin <i>et al.</i> 2009 ¹⁹	Randomised, double-blind, parallel-group/12 weeks	Moderate and severe COPD (> 30 - < 70) mean FEV ₁ : NS GOLD stage II: 23.9 n=255	1. Tiotropium 18 μ g qd 2. Tiotropium 18 μ g qd + formoterol 12 μ g bid	Spirometry (FEV ₁ , FVC); diary card recorded PEF; symptoms and use of salbutamol as rescue; dyspnoea (TDI); health status (SGRQ); safety
Vogelmeier <i>et al.</i> 2008 ⁸	Randomised, partially-blinded, placebo-controlled, parallel-group/24 weeks	Moderate and severe COPD (< 70) mean FEV ₁ : 51.6 GOLD stage II: NS n=847	1. Tiotropium 18 μ g qd 2. Formoterol 12 μ g bid 3. Tiotropium 18 μ g qd + formoterol 10 μ g bid 4. Placebo	Spirometry (FEV ₁ , FVC); health status (SGRQ); COPD exacerbations; symptom scores; use of salbutamol as rescue; PEF; 6-min walking distance
Wang <i>et al.</i> 2010 ⁶	Meta-analysis	n=1868	1. Tiotropium 18 μ g qd 2. Tiotropium 18 μ g qd + formoterol/arformoterol (10-20 μ g bid; 12 μ g qd)	Spirometry (FEV ₁ , FVC); dyspnoea (TDI); exacerbations
Nebulised arformoterol or formoterol plus tiotropium				
Tashkin <i>et al.</i> 2009 ¹⁵	Randomised, modified-blind, parallel-group/2 weeks	COPD (≤ 65) mean FEV ₁ : 45.4 GOLD stage II: NS n=235	1. Tiotropium 18 μ g qd 2. Nebulised arformoterol 15 μ g bid 3. Tiotropium 18 μ g qd + nebulised arformoterol 15 μ g bid	Spirometry (FEV ₁ , FVC, IC); dyspnoea (TDI); use of levalbuterol as rescue; safety
Tashkin <i>et al.</i> 2008 ²⁰	Randomised, double-blind, parallel-group/6 weeks	COPD (≥ 25 - < 65) mean FEV ₁ : 38.4 GOLD stage II: NS n=130	1. Tiotropium 18 μ g qd 2. Tiotropium 18 μ g qd + nebulised formoterol 20 μ g bid	Spirometry (FEV ₁ , FVC); dyspnoea (TDI); health status (SGRQ); diary card recorded symptoms and use of salbutamol as rescue; safety
Hanania <i>et al.</i> 2009 ¹⁷	Randomised, double-blind, parallel-group/6 weeks	COPD (≥ 25 - < 65) mean FEV ₁ : 46.1 GOLD stage II: NS n=155	1. Tiotropium 18 μ g qd 2. Tiotropium 18 μ g qd + nebulised formoterol 20 μ g bid	Spirometry (FEV ₁ , FVC, IC); dyspnoea (TDI); daily symptom scores; health status (SGRQ); use of salbutamol as rescue; safety
Salmeterol plus tiotropium				
van Noord <i>et al.</i> 2010 ²²	Randomised, double-blind, crossover/6-week treatment periods	COPD (≤ 60) mean FEV ₁ : 45 GOLD stage II: 33 n=95	1. Tiotropium 18 μ g qd 2. Salmeterol 50 μ g bid 3. Tiotropium 18 μ g qd + salmeterol 50 μ g bid 4. Tiotropium 18 μ g qd + salmeterol 50 μ g qd	Spirometry (FEV ₁ , FVC); dyspnoea (TDI), diary card recorded PEF; use of salbutamol as rescue
van Noord <i>et al.</i> 2005 ²¹	Randomised, double-blind, crossover/6-week treatment periods	COPD (NS) mean FEV ₁ : 39 GOLD stage II: NS n=97	1. Tiotropium 18 μ g qd 2. Salmeterol 50 μ g bid 3. Tiotropium 18 μ g qd + salmeterol 50 μ g qd 4. Tiotropium 18 μ g qd + salmeterol 50 μ g bid	Dyspnoea (TDI); use of salbutamol as rescue

Table 1. Clinical trial characteristics: randomised studies of long-acting β_2 -agonists combined with long-acting muscarinic antagonists (continued)

Authors	Design/duration	Patient characteristics (FEV ₁ % predicted*) mean FEV ₁ # GOLD stage II† patient number	Treatment groups	Outcomes measured
Aaron <i>et al.</i> 2007 ⁷	Randomised, double-blind/1 year	Moderate or severe COPD (<65) mean FEV ₁ : 42 GOLD stage II: NS n=449	1. Tiotropium 18 μ g qd 2. Tiotropium 18 μ g qd + salmeterol 50 μ g bid 3. Tiotropium 18 μ g qd + salmeterol/fluticasone propionate 50/500 μ g bid	Proportion of patients experiencing an exacerbation; lung function; health status (SGRQ); hospitalisations; dyspnoea (TDI); safety
Indacaterol plus tiotropium Mahler <i>et al.</i> 2011 ¹⁸	Randomised, double-blind (two studies of identical design)/12 weeks	Moderate and severe COPD (NS) Mean FEV ₁ : 49 (Study 1 and Study 2) GOLD stage II: NS n=1134 (study 1), n=1142 (study 2)	1. Open-label tiotropium 18 μ g qd + placebo 2. Open-label tiotropium 18 μ g qd + indacaterol 150 μ g qd	Spirometry (FEV ₁ , IC); use of albuterol as rescue

bid=twice daily, COPD=chronic obstructive pulmonary disease, FEV₁=forced expiratory volume in 1 second, FVC=forced vital capacity, IC=inspiratory capacity, NS=not stated, PEF=peak expiratory flow rate, qd=once daily, SGRQ=St George's Respiratory Questionnaire, TDI=transitional dyspnoea index.

*FEV₁ % predicted as inclusion criteria.

#Mean FEV₁ % predicted of recruited patients.

†Proportion of patients with moderate COPD, classified as GOLD stage II (FEV₁/FVC <0.70; 50% \leq FEV₁<80% predicted).

Beyond spirometry: the effects of LABA/LAMA combination therapy


Inspiratory capacity and reduction of hyperinflation

In patients with COPD, delayed lung emptying can lead to an increase in end-expiratory lung volume (EELV) and consequently lung overinflation or 'hyperinflation'. Increases in EELV correlate with decreases in inspiratory capacity (IC) in COPD, and patients can experience respiratory discomfort.¹²⁻¹⁴ Therapies that improve IC (and reduce hyperinflation) may therefore help to lessen the respiratory discomfort experienced by patients with COPD.

There is limited clinical evidence for the effect of LABA/LAMA therapy on EELV/IC outcomes; however, treatment with tiotropium and formoterol/arformoterol combination has demonstrated efficacy over LABA monotherapy in three 2-week studies and one 6-week study.^{2,15-17} In the first 2-week study, tiotropium with add-on formoterol once daily in the morning was shown to improve IC for >12 hrs compared with tiotropium alone, with further improvements in patients who received add-on formoterol twice daily; however, the duration of improvement of IC was <10 hrs following the evening formoterol dose (Figure 1).² There was no significant difference in trough IC response among the three treatment groups.

In the second 2-week study, nebulised arformoterol and tiotropium combination therapy provided a mean improvement from baseline in IC of 0.29 \pm 0.39L compared with 0.20 \pm 0.32L (arformoterol) and 0.19 \pm 0.32L (tiotropium).¹⁵ The third 2-week study assessed the impact of tiotropium/formoterol combination therapy versus formoterol monotherapy on dynamic hyperinflation and exercise endurance in COPD patients.¹⁶ IC was measured using constant-speed treadmill tests to the limit of tolerance (Tlim), or a maximum of 20 mins. Percentage improvement from baseline in Tlim was significantly greater after

Figure 1. Mean IC before (24-hr baseline) and at the end of 2-week treatment periods (means adjusted for period, centre, and patient within centre).² *p<0.05 tiotropium + formoterol twice daily (bid) vs. tiotropium; †p<0.05 tiotropium + formoterol once daily (qd) vs. tiotropium; ‡p<0.05 tiotropium + formoterol twice daily vs. tiotropium + formoterol once daily. IC=inspiratory capacity



combination therapy than with formoterol alone (124 \pm 27% vs. 68 \pm 14%, p<0.05). EELV was further reduced with the combination versus monotherapy (p<0.05). In addition, a 6-week study demonstrated a significant improvement in post-dose IC with nebulised formoterol plus tiotropium compared with tiotropium alone (p<0.005; peak IC improvement 230mL with combination therapy at week 6 vs. monotherapy).¹⁷

Furthermore, two 12-week studies demonstrated the superior efficacy of tiotropium and indacaterol combination therapy over LAMA monotherapy.¹⁸ At week 12, addition of indacaterol to tiotropium provided significantly greater increases in trough IC (130mL and 100mL for studies 1 and 2, respectively)

compared with tiotropium alone (both $p < 0.01$). Clinical evidence thus indicates that LABA/LAMA combination therapy improves IC (and, used as a surrogate marker, can therefore be considered to reduce hyperinflation) in patients with COPD.

Dyspnoea

Dyspnoea is a common and troublesome manifestation of COPD and relief from dyspnoea is an important goal of pharmacotherapy.¹ Studies of LABA/LAMA combination therapy that included dyspnoea as an endpoint are detailed in Table 2. All studies of tiotropium and formoterol/arformoterol combination therapy improved dyspnoea (assessed by the Transitional Dyspnoea Index (TDI)) to a greater extent than either monotherapy.^{6,15-17,19,20} Two further studies of tiotropium plus salmeterol (once or twice a day) also showed a marked improvement in dyspnoea with combination therapy over either monotherapy.^{21,22} In a study by Aaron *et al.*,⁷ no significant

difference in mean TDI total score was demonstrated between tiotropium plus salmeterol, tiotropium plus salmeterol/fluticasone and tiotropium alone; however, it should be noted that a large number of patients discontinued during this study (61.0% completed), making it difficult to draw firm conclusions on efficacy between treatment groups.

A greater proportion of patients achieved the minimum clinically important difference (MCID) in TDI total score of ≥ 1 unit with combination therapies than with LABA or LAMA monotherapy. The proportion of patients achieving the MCID in TDI total score was 31.1–57.1% for tiotropium monotherapy, 48.0–66.7% for LABA monotherapy, and 57.7–77.9% for LABA/LAMA combination therapy.^{17,19,20,22}

Overall, LABA/LAMA combination therapy demonstrated clinically relevant improvements in dyspnoea, greater than those seen with LABA or tiotropium alone.

Table 2. Dyspnoea reported in long-acting β_2 -agonist/long-acting muscarinic antagonist (LABA/LAMA) combination therapy clinical trials

Authors	Duration	Mean BDI score	Mean TDI total score	Patients achieving MCID (change ≥ 1 unit) in TDI total score, n (%)
Berton <i>et al.</i> 2010 ¹⁶	2 weeks	<9*	Formoterol: 2.9 Tiotropium + formoterol: 3.8 ($p=0.054$ vs. formoterol)	–
Tashkin <i>et al.</i> 2009 ¹⁵	2 weeks	Nebulised arformoterol: 5.8 Tiotropium: 5.8 Tiotropium + nebulised arformoterol: 5.5	Nebulised arformoterol: 2.3 Tiotropium: 1.8 Tiotropium + nebulised arformoterol: 3.1	Nebulised arformoterol: 50 (66.7%) Tiotropium: 44 (57.1%) Tiotropium + nebulised arformoterol: 60 (77.9%) (statistically significant vs. tiotropium; 95% CI 0.06, 0.35)
Tashkin <i>et al.</i> 2008 ²⁰	6 weeks	Tiotropium: 6.4 Tiotropium + nebulised arformoterol: 6.3	Tiotropium: 0.16 Tiotropium + nebulised arformoterol: 2.3 (LS mean difference vs. tiotropium=1.80; 95% CI, 0.859 to 2.740, $p=0.0002$)	Tiotropium: 63 (31.1%) Tiotropium + nebulised arformoterol: 66 (57.7%)
Hanania <i>et al.</i> 2009 ¹⁷	6 weeks	Tiotropium: 5.80 Tiotropium + formoterol: 5.92	Tiotropium: 0.87 Tiotropium + formoterol: 1.59 (LS mean difference vs. tiotropium=0.72; -0.16 to 1.60 , $p=0.11$)	Tiotropium: 34 (47.2%) Tiotropium + formoterol: 45 (58.4%)
van Noord <i>et al.</i> 2010 ²²	6 weeks	7.0	Tiotropium: 1.18 Salmeterol bid: 0.97 Tiotropium + salmeterol qd: 2.56 Tiotropium + salmeterol bid: 2.71 ($p < 0.005$ for tiotropium + salmeterol (qd or bid) vs. either monotherapy)	Salmeterol bid: 95 (48%) Tiotropium: 95 (57%) Tiotropium + salmeterol qd: 95 (67%) Tiotropium + salmeterol bid: 95 (72%)
van Noord <i>et al.</i> 2005 ²¹	6 weeks	6.9	– (tiotropium + salmeterol (bid or qd) superior to either monotherapy in perceived dyspnoea)	–
Tashkin <i>et al.</i> 2009 ¹⁹	12 weeks	Tiotropium: 5.67 Tiotropium + formoterol: 5.34	Tiotropium: 1.53 Tiotropium + formoterol: 1.60 (difference between treatments significant only at week 8 (1.86 tiotropium + formoterol vs. 1.01 tiotropium; 95% CI 0.18 to 1.51; $p=0.013$)	–
Aaron <i>et al.</i> 2007 ⁷	1 year	Tiotropium: 6.3 Tiotropium + salmeterol: 6.5 Tiotropium + salmeterol/fluticasone: 6.5	Tiotropium: 1.78 Tiotropium + salmeterol: 1.40 Tiotropium + salmeterol/fluticasone: 1.84 (no significant difference between treatment groups)	–
Wang <i>et al.</i> 2010 ⁶	Meta-analysis	–	– Mean change in TDI greater with tiotropium + formoterol vs. tiotropium ($p < 0.0001$)	– Larger proportion of patients receiving tiotropium + formoterol achieved clinically significant change in TDI vs. tiotropium ($p < 0.0001$)

BDI=baseline dyspnoea index, bid=twice daily, MCID=minimum clinically important difference, qd=once daily, TDI=transitional dyspnoea index.

*Specified as inclusion criteria, value not stated.

Symptoms, symptom scores, and rescue medication use

Several studies have assessed the impact of LABA/LAMA combination therapy on patient-reported respiratory symptoms, and on the use of rescue medication to relieve symptoms.

In a 6-week study, shortness of breath, chest tightness, night-time awakenings, and total respiratory symptom scores all significantly improved with nebulised formoterol plus tiotropium compared with tiotropium alone. Cough scores also improved, but did not significantly differ between treatment groups.²⁰ Another 6-week study found no difference in overall symptom scores following treatment with nebulised formoterol plus tiotropium or tiotropium monotherapy.¹⁷ In a 12-week study, a combination of formoterol and tiotropium significantly improved symptom scores from baseline to last study visit compared with tiotropium alone, although there was no difference between groups in the number of nocturnal awakenings.¹⁹ A longer-term study (6 months) showed no difference in average daily symptom scores for patients receiving combination therapy (formoterol plus tiotropium) compared with those receiving bronchodilator monotherapy.⁸

Short-acting β_2 -agonists (e.g. salbutamol/albuterol) are often used by COPD patients as rescue medication to help alleviate symptoms. Short-term (≤ 6 weeks) and longer-term (≥ 12 weeks) studies demonstrated a decrease in rescue medication use with tiotropium and LABA (formoterol/arformoterol/salmeterol) combination therapy compared with either monotherapy, which may be associated with the improvements in symptoms observed with LABA/LAMA combination therapies in these studies.^{2,8,15,17,19-23}

The reduction in rescue medication use in a 2-week and 6-week study of tiotropium plus formoterol compared with tiotropium is shown in Figure 2.^{2,17} Two 12-week studies also demonstrated a numerically greater reduction in rescue medication use with tiotropium/indacaterol combination therapy compared with tiotropium alone.¹⁸

Overall, there was a trend for improvement in symptom scores and rescue medication use in favour of combination therapy compared with monotherapy.


Exacerbations

Prevention of exacerbations is one of the most important goals of COPD management. However, only a small number of LABA/LAMA combination studies have included exacerbations as an endpoint, and across these studies the definition of an exacerbation differs (or is not detailed), making it difficult to draw conclusions on efficacy (Table 3). Overall, no significant difference was demonstrated in the incidence of exacerbations or the time to first exacerbation between LABA/LAMA combination treatments and monotherapy.^{6-8,19} Further studies assessing the impact of combination bronchodilator therapy on COPD exacerbations are required.

Health status

As COPD progresses, the ability to function and perform activities on a daily basis reduces and, consequently, health status

Figure 2. Mean number of puffs of rescue medication (salbutamol) per day over (a) 2-week² and (b) 6-week¹⁷ treatment periods. NS=not significant, SEM=standard error of mean. * $p < 0.05$ vs. tiotropium



deteriorates.^{1,24} The St George's Respiratory Questionnaire (SGRQ) is a validated measure of health status that is frequently used in clinical trials.²⁴ The MCID is defined as a decrease from baseline or placebo of ≥ 4 points in the SGRQ total score.

A total of five studies have examined the effect of LABA/LAMA treatment on health status, and all used the SGRQ as the assessment tool.^{7,8,17,19,20} In longer-term studies (≥ 12 weeks), both LAMA (tiotropium) and LABA/LAMA combination therapies improved total SGRQ from baseline (Table 4).^{7,8,19} In two studies the improvement in SGRQ with tiotropium plus formoterol or tiotropium plus salmeterol was greater than with tiotropium alone, with the difference attaining statistical significance in one study.^{7,19} These two studies also reported the values for change in total SGRQ, indicating that the total scores were around the MCID for tiotropium (improvement of 3.8 and 4.5) and well above the MCID for tiotropium plus formoterol or salmeterol (4.81 and 6.3).^{7,19} These results indicate that the improvement in SGRQ total score was clinically significant with LABA/LAMA treatment. In a third long-term study, the improvements in SGRQ total score with tiotropium, formoterol, and tiotropium plus formoterol were significantly greater than with placebo, but did not show any significant difference between treatment groups.⁸ The lack of a consistent statistically significant difference in improvement in the SGRQ score between LAMA and LABA/LAMA treatment may be

Table 3. Exacerbations reported in long-acting β_2 -agonist/long-acting muscarinic antagonist (LABA/LAMA) combination therapy clinical trials

Authors	Duration	Exacerbation definition	Incidence of exacerbations, n (%)	Mean duration of exacerbation	Time to first exacerbation (days)
Tashkin <i>et al.</i> 2009 ¹⁹	12 weeks	–	Tiotropium: 14 (11%) Tiotropium + formoterol: 21 (17%) (no significant difference between treatment groups; $p=0.149$)	Tiotropium: 19.4 days Tiotropium + formoterol: 16.2 days	–
Vogelmeier <i>et al.</i> 2008 ⁸	24 weeks	'COPD exacerbation days' = days with at least two symptoms (0-3 scale of breathlessness, cough, wheeze, amount of sputum, colour of sputum) recorded as being worse than usual	Tiotropium: 23 (10.4%) Formoterol: 17 (8.1%) Tiotropium + formoterol: 13 (6.3%) Placebo: 30 (14.4%)	Formoterol: 2.4† Tiotropium: 3.3† Tiotropium + formoterol: 3.3†	–
Aaron <i>et al.</i> 2007 ⁷	1 year	At least one exacerbation of COPD requiring treatment with systemic steroids or antibiotics within the 12 months before randomisation	Tiotropium: 98 (62.8%) Tiotropium + salmeterol: 96 (64.8%) Tiotropium + salmeterol/fluticasone: 87 (60.0%) (no significant difference in absolute risk reduction between either combination therapy and tiotropium)	–	Tiotropium: 130 Tiotropium + salmeterol: 128 Tiotropium + salmeterol/fluticasone: 217 (compared with tiotropium, tiotropium + fluticasone/salmeterol did not statistically prolong time to first exacerbation; adjusted HR=0.80 (95% CI 0.60 to 1.08, $p=0.15$))
Wang <i>et al.</i> 2010 ⁶	Meta-analysis	–	Tiotropium: 8.9%* Tiotropium + formoterol: 8.3%* (no difference between treatment groups: OR=0.93, 95% CI 0.45 to 1.93, $p=0.85$)	–	–

HR=hazard ratio, OR=odds ratio. *Overall cumulative incidence. †COPD exacerbation days (% of treatment days).

because of the substantial improvement attained in both treatment groups, making differentiation between treatments difficult. Moreover, as assessment of health status was not the primary endpoint in these studies, it is unlikely the studies were sufficiently powered to show a difference in SGRQ total score between active treatments.

Two short-term studies (6 weeks) of tiotropium plus nebulised formoterol versus tiotropium monotherapy found no difference in SGRQ scores from baseline to week 6 or between treatments.^{17,20} This is perhaps not surprising given the short duration of the studies; the effect of treatment on health status

may not be apparent after only 6 weeks of treatment.

The improvement in SGRQ total score with LABA/LAMA treatment appears to be driven by the effect on the symptom domain of the SGRQ rather than the domains of activity or impact. Indeed, several studies have shown an improvement in the symptom domain with LABA/LAMA treatment compared with LAMA monotherapy, which was statistically significant in two studies.^{8,19,20}

The studies identified here all used the SGRQ to assess health status. This is a comprehensive questionnaire that takes time to complete and score, limiting its use in routine clinical practice.¹⁰

Table 4. Health status reported in long-acting β_2 -agonist/long-acting muscarinic antagonist (LABA/LAMA) combination therapy clinical trials

Authors	Duration	Total SGRQ score	SGRQ domain score
Tashkin <i>et al.</i> 2008 ²⁰	6 weeks	– No significant difference between treatment groups (tiotropium; tiotropium + nebulised formoterol)	Symptom score: tiotropium: +0.5; tiotropium + nebulised formoterol: –5.8 ($p=0.04$, 95% CI, –12.2 to –0.35) No significant difference between treatment groups for activity or impact scores
Hanania <i>et al.</i> 2009 ¹⁷	6 weeks	– No significant difference between treatment groups	– No significant difference between treatment groups (tiotropium; tiotropium + nebulised formoterol)
Tashkin <i>et al.</i> 2009 ¹⁹	12 weeks	Tiotropium: –3.80 Tiotropium + formoterol: –4.81 No significant difference between treatment groups	Symptom score: tiotropium: –3.97; tiotropium + formoterol: –8.33 ($p<0.05$ vs. tiotropium alone) No significant difference between treatment groups for activity or impact scores
Vogelmeier <i>et al.</i> 2008 ⁸	24 weeks	– No significant difference between treatment groups (tiotropium; formoterol; tiotropium + formoterol)	– Symptom score: significantly different from placebo for all treatment groups (tiotropium; formoterol; tiotropium + formoterol) No significant difference between treatment groups for activity or impact scores
Aaron <i>et al.</i> 2007 ⁷	1 year	Tiotropium: –4.5 Tiotropium + salmeterol: –6.3 ($p=0.02$ vs. tiotropium) Tiotropium + salmeterol/fluticasone: –8.6 ($p=0.01$ vs. tiotropium)	–

SGRQ=St George's Respiratory Questionnaire.

The effect of LABA/LAMA combination on health status measured with shorter questionnaires designed for use in clinical practice such as the Clinical COPD Questionnaire (CCQ)²⁵ and the COPD Assessment Test (CAT)²⁶ are currently being investigated.

Safety

Any new LABA/LAMA combination must also take safety into consideration as additional efficacy or health status benefits must not be at the expense of safety. Several studies have shown no increase in frequency or severity of adverse events with tiotropium plus formoterol compared with tiotropium alone.^{2,6,8,15,17,19,20,23} The most common adverse event with both treatments was COPD exacerbation, and the combination was not associated with any clinically relevant changes in laboratory variables.^{2,6,8,15,17,19,20,23} Similar findings were recently reported in two large 12-week studies in which concurrent treatment with indacaterol and tiotropium did not increase the incidence of adverse events, serious adverse events, notable laboratory variables (plasma potassium and blood glucose), and ECG findings (QTc interval) compared with tiotropium alone.¹⁸ In another recent study, QVA149, a fixed-dose combination of indacaterol and a LAMA (NVA237), was well tolerated in patients with COPD, with a cardiovascular safety profile and overall adverse event rate similar to placebo.²⁷

LABA/LAMA combination therapy and the future of COPD management

Current guidelines recommend the addition of a second bronchodilator to initial monotherapy in moderate COPD in order to maximise bronchodilation,¹ and the impact of LABA/LAMA combinations on FEV₁ has been established.⁵ The studies detailed in this review indicate that LABA/LAMA combinations are also effective at improving patient-centred outcomes; however, additional studies assessing these outcomes are needed.

The trials considered here have reported on the free combination of a LABA (salmeterol or arformoterol/formoterol (once or twice a day) or indacaterol (once a day)) with tiotropium. Fixed-dose LABA/LAMA combinations are not currently available; however, the convenience of both agents in a single device may increase compliance and help to simplify COPD management further. It is likely that treatment options for COPD patients will expand further in the future to include free and fixed combinations of new LABAs or LAMAs (including once-daily fixed-dose combinations), which may lead to even greater improvements in patient-centred outcomes.

There are currently a number of LABA/LAMA fixed-dose combinations in development for COPD.²⁸ QVA149 (an inhaled fixed-dose combination comprising two 24-hr agents, the LABA indacaterol and the LAMA NVA237) has demonstrated rapid and sustained bronchodilation with significant improvements compared with indacaterol monotherapy.²⁹ Phase III trials in COPD to assess the long-term efficacy and safety of once-daily QVA149 are in progress. Initial studies with a once-daily fixed-dose combination of the LABA olodaterol and tiotropium have

also demonstrated superior bronchodilation in COPD compared with tiotropium alone.³⁰ Other COPD treatment options in development include formoterol plus the LAMA acridinium, and the LABA vilanterol plus the LAMA GSK-573719.³¹ Furthermore, novel compounds are being developed which act as dual antimuscarinic/ β_2 -adrenergic receptor agonists (e.g. GSK-961081 and PF-3429281).^{31,32}

Despite the promising improvements in lung function demonstrated with current treatments, the question remains whether interventions that significantly improve FEV₁ are also associated with improvements in other outcome measures. Several studies have demonstrated a significant relationship between poor lung function and a decline in health status in patients with COPD,³³⁻³⁸ however, there is limited evidence that changes in lung function associated with a therapeutic intervention correlate with changes in patient-centred outcomes. In a recent analysis, pooled data from three indacaterol studies (12, 26, and 52 weeks in duration) were used to examine relationships between change from baseline of FEV₁ and clinical outcomes (dyspnoea (TDI score), health status (SGRQ score) and exacerbations).³⁹ The results of this analysis suggest that treatment interventions that significantly improve FEV₁ are likely to be associated with greater improvements in patient-centred outcomes.

Conclusions

Studies of LABA/LAMA combinations to date indicate that combining different classes of bronchodilator results in significantly greater improvements in lung function and other meaningful outcomes such as IC, dyspnoea, symptom scores, rescue medication use, and health status compared with individual drugs. Additional studies assessing the impact of LABA/LAMA combination therapies on COPD exacerbations, using a standardised definition of an exacerbation, are clearly needed. Other elements of importance to patients such as exercise capacity, hospitalisations, depression, and pain are likely to be explored.

Bronchodilators remain central to the symptomatic management of COPD and as such, LABA/LAMA combination therapy could play an important role in maximising bronchodilation and improving IC, symptoms, health status and dyspnoea in patients with COPD. The last item is particularly important in those patients with moderate-to-severe disease, whose dyspnoea during daily activities is not relieved by short-acting bronchodilators and who require more effective LABA, LAMA, and combination treatments. The value of FEV₁ alone as a surrogate marker of COPD is limited, and patient-centred outcomes are important for both adequate recognition of the disease and effective treatment of patients. Importantly, guidelines also now recognise the significance of such patient-centred outcomes in clinical trials of COPD therapies, with a view that they will better reflect the overall well-being of the patient, beyond lung function measurements alone.

Handling editor Irem Patel

Acknowledgements Helen Attisha (ACUMED) assisted in the preparation of the first draft of the manuscript, and also co-ordinated the authors' input into this and subsequent drafts. Mark Fedele (Novartis) critically reviewed the manuscript drafts. Neither fulfil the three ICMJE criteria for authorship, but we are very grateful indeed for their assistance.

Conflicts of interest TvdM has received research grants from AstraZeneca (AZ), GlaxoSmithKline (GSK), Nycomed, and MSD; consultancy fees from AZ, Nycomed, MSD, and Novartis; and speaker fees from AZ, GSK, Nycomed and MSD. MC has received honoraria for speaking and consulting and/or financial support for attending meetings from Abbott, AZ, Boehringer Ingelheim, Chiesi Farmaceutici, Dey, Gentili, GSK, Lallemand, Menarini Farmaceutici, Mundipharma, Novartis, Nycomed, Pfizer, Sanovel, Sigma Tau, and Valeas.

Contributorship The authors, Thys van der Molen and Mario Cazzola, were both involved in the concept and design of this article and the interpretation of the data. Both authors revised the article critically for important intellectual content, and gave their final approval of the version to be published.

Funding This study was funded by Novartis Pharma AG, Basel, Switzerland; development of this manuscript was also supported by Novartis.

References

- GOLD. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. 2009.
- van Noord JA, Aumann JL, Janssens E, *et al.* Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. *Chest* 2006;**129**(3):509-17. <http://dx.doi.org/10.1378/chest.129.3.509>
- Cazzola M, Matera MG. Long-acting bronchodilators are the first-choice option for the treatment of stable COPD. *Chest* 2004;**125**(1):9-11. <http://dx.doi.org/10.1378/chest.125.1.9>
- Hanania NA, Donohue JF. Pharmacologic interventions in chronic obstructive pulmonary disease: bronchodilators. *Proc Am Thorac Soc* 2007;**4**(7):526-34. <http://dx.doi.org/10.1513/pats.200701-016FM>
- Cazzola M, Molimard M. The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD. *Pulm Pharmacol Ther* 2010;**23**(4):257-67. <http://dx.doi.org/10.1016/j.pupt.2010.03.003>
- Wang J, Jin D, Zuo P, *et al.* Comparison of tiotropium plus formoterol to tiotropium alone in stable chronic obstructive pulmonary disease: a meta-analysis. *Respirology* 2010;**16**(2):350-8. <http://dx.doi.org/10.1111/j.1440-1843.2010.01912.x>
- Aaron SD, Vandemheen KL, Fergusson D, *et al.* Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. *Ann Intern Med* 2007;**146**(8):545-55.
- Vogelmeier C, Kardos P, Harari S, *et al.* Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. *Respir Med* 2008;**102**(11):1511-20. <http://dx.doi.org/10.1016/j.rmed.2008.07.020>
- Jones PW, Agustí AG. Outcomes and markers in the assessment of chronic obstructive pulmonary disease. *Eur Respir J* 2006;**27**(4):822-32. <http://dx.doi.org/10.1183/09031936.06.00145104>
- Cazzola M, MacNee W, Martinez FJ, *et al.* Outcomes for COPD pharmacological trials: from lung function to biomarkers. *Eur Respir J* 2008;**31**(2):416-69. <http://dx.doi.org/10.1183/09031936.00099306>
- Jones PW, Kaplan RM. Methodological issues in evaluating measures of health as outcomes for COPD. *Eur Respir J Suppl* 2003;**41**:13-8s. <http://dx.doi.org/10.1183/09031936.03.00077803>
- Calverley PM. Dynamic hyperinflation: is it worth measuring? *Proc Am Thorac Soc* 2006;**3**(3):239-44. <http://dx.doi.org/10.1513/pats.200508-084SF>
- Duranti R, Filippelli M, Bianchi R, *et al.* Inspiratory capacity and decrease in lung hyperinflation with albuterol in COPD. *Chest* 2002;**122**(6):2009-14. <http://dx.doi.org/10.1378/chest.122.6.2009>
- Stubbing DG, Pengelly LD, Morse JL, Jones NL. Pulmonary mechanics during exercise in subjects with chronic airflow obstruction. *J Appl Physiol* 1980;**49**(3):511-5.
- Tashkin DP, Donohue JF, Mahler DA, *et al.* Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD. *Respir Med* 2009;**103**(4):516-24. <http://dx.doi.org/10.1016/j.rmed.2008.12.014>
- Berton DC, Reis M, Siqueira AC, *et al.* Effects of tiotropium and formoterol on dynamic hyperinflation and exercise endurance in COPD. *Respir Med* 2010;**104**(9):1288-96. <http://dx.doi.org/10.1016/j.rmed.2010.05.017>
- Hanania NA, Boota A, Kerwin E, Tomlinson L, is-Mize K. Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: results from a 6-week, randomized, placebo-controlled, clinical trial. *Drugs* 2009;**69**(9):1205-16. <http://dx.doi.org/10.2165/00003495-200969090-00005>
- Mahler DA, D'Urzo A, Peckitt C, *et al.* Combining once-daily bronchodilators in COPD: indacaterol plus tiotropium versus tiotropium alone. *Am J Respir Crit Care Med* 2011;**183**:A1591
- Tashkin DP, Pearle J, Iezzoni D, Varghese ST. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. *COPD* 2009;**6**(1):17-25. <http://dx.doi.org/10.1080/15412550902724073>
- Tashkin DP, Littner M, Andrews CP, *et al.* Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial. *Respir Med* 2008;**102**(4):479-87. <http://dx.doi.org/10.1016/j.rmed.2007.12.019>
- van Noord J, Aumann L, Janssens E, *et al.* Combination therapy of tiotropium plus salmeterol superior to single agent therapy in terms of dyspnea improvement in COPD (abstract). *Chest* 2005;**128**:177S.
- van Noord JA, Aumann JL, Janssens E, *et al.* Combining tiotropium and salmeterol in COPD: Effects on airflow obstruction and symptoms. *Respir Med* 2010;**104**(7):995-1004. <http://dx.doi.org/10.1016/j.rmed.2010.02.017>
- van Noord JA, Aumann JL, Janssens E, *et al.* Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. *Eur Respir J* 2005;**26**(2):214-22. <http://dx.doi.org/10.1183/09031936.05.00140404>
- Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St George's Respiratory Questionnaire. *Am Rev Respir Dis* 1992;**145**(6):1321-7.
- van der Molen T, Willemse BW, Schokker S, *et al.* Development, validity and responsiveness of the Clinical COPD Questionnaire. *Health Qual Life Outcomes* 2003;**1**:13. <http://dx.doi.org/10.1186/1477-7525-1-13>
- Jones PW, Harding G, Berry P, *et al.* Development and first validation of the COPD Assessment Test. *Eur Respir J* 2009;**34**(3):648-54. <http://dx.doi.org/10.1183/09031936.00102509>
- Van de Maele B, Fabbri LM, Martin C, *et al.* Cardiovascular safety of QVA149, a combination of indacaterol and NVA237, in COPD patients. *COPD* 2010;**7**(6):418-27. <http://dx.doi.org/10.3109/15412555.2010.528812>
- Cazzola M, Matera MG. Emerging inhaled bronchodilators: an update. *Eur Respir J* 2009;**34**(3):757-69. <http://dx.doi.org/10.1183/09031936.00013109>
- van Noord JA, Buhl R, Laforce C, *et al.* QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. *Thorax* 2010;**65**(12):1086-91. <http://dx.doi.org/10.1136/thx.2010.139113>
- Maltais F, Beck E, Webster D, *et al.* Four weeks once daily treatment with tiotropium+olodaterol (BI 1744) fixed dose combination compared with tiotropium in COPD patients (abstract). *Eur Respir J* 2010;**36**:5557.
- Clinicaltrials.gov. www.clinicaltrials.gov 2011.
- Phillip J, Gray A, Clarke N, Yeadon M, Perros-Huguet C. Demonstration of dual pharmacology in vivo of PF-3429281: a novel inhaled dual antimuscarinic/ β 2 agonist (abstract). *Eur Respir J* 2010;**36**:1231.
- Anzueto A, Leimer I, Kesten S. Impact of frequency of COPD exacerbations on pulmonary function, health status and clinical outcomes. *Int J Chron Obstruct Pulmon Dis* 2009;**4**:245-51. <http://dx.doi.org/10.2147/COPD.S4862>
- Camargo CA Jr, Tsai CL, Clark S, Kenney PA, Radeos MS. Spirometric correlates of dyspnea improvement among emergency department patients with chronic obstructive pulmonary disease exacerbation. *Respir Care* 2008;**53**(7):892-6.
- Niewoehner DE. Relation of chronic obstructive pulmonary disease exacerbations to FEV(1)--an intricate tango. *Respiration* 2009;**77**(2):229-35. <http://dx.doi.org/10.1159/000162877>
- Watson L, Schouten JP, Lofdahl CG, *et al.* Predictors of COPD symptoms: does the sex of the patient matter? *Eur Respir J* 2006;**28**(2):311-18. <http://dx.doi.org/10.1183/09031936.06.00055805>
- Mannino DM, Davis KJ. Lung function decline and outcomes in an elderly population. *Thorax* 2006;**61**(6):472-7. <http://dx.doi.org/10.1136/thx.2005.052449>
- McGlone S, Venn A, Walters EH, Wood-Baker R. Physical activity, spirometry and quality-of-life in chronic obstructive pulmonary disease. *COPD* 2006;**3**(2):83-8. <http://dx.doi.org/10.1080/15412550600651263>
- Jones PW, Donohue J, Nedelman J, Pinault G, Pascoe S. Correlating changes in lung function with patient reported outcomes in COPD (abstract). *Thorax* 2010; **65**:A141. <http://dx.doi.org/10.1136/thx.2010.150987.49>